Table 1.
Agents approved or in development active against CRE.
| Approved Agent | Class | Developmental Agent | Class |
|---|---|---|---|
| Ceftazidime-avibactam | β-lactam-β-lactamase inhibitor | Apramycin | Aminoglycoside |
| Cefiderocol | Siderophore cephalosporin | Arbekacin inhalation | Aminoglycoside |
| Ciprofloxacin | Fluoroquinolone | BOS-228 | Monobactam |
| Colistin | Polymyxin | Cefepime-AAI101 | β-lactam-β-lactamase inhibitor |
| Doxycycline | Tetracycline | Cefepime-VNRX5133 | β-lactam-β-lactamase inhibitor |
| Imipenem-relebactam | β-lactam-β-lactamase inhibitor | Cefepime-zidebactam | β-lactam-PBP2 inhibitor |
| Levofloxacin | Fluoroquinolone | Ceftibuten-VNRX7145 | β-lactam-β-lactamase inhibitor |
| Meropenem-vaborbactam | β-lactam-β-lactamase inhibitor | Cefpodoxime-ETX0282 | β-lactam- β-lactamase inhibitor |
| Plazomicin | Aminogycoside | FG-LpxC-UTI | LpxC inhibitor |
| Tigecycline | Tetracycline | Fosfomycin 1 | Phosphoenolpyruvate synthetase inhibitor |
| KBP-7072 | Tetracycline | ||
| Meropenem-nacubactam | β-lactam-β-lactamase inhibitor | ||
| QPX2015-QPX7728 | β-lactam-β-lactamase inhibitor | ||
| SPR206 | Polymyxin |
1 IV fosfomycin is currently available in many regions outside the United States.